Curetis NV (CURE)

Curetis N.V., a commercial-stage molecular diagnostics company, provides solutions for laboratories, pharma-companies, and public hospitals in Germany and internationally. The company develops, manufactures, and commercializes molecular microbiology solutions for severe infectious diseases in hospitalized patients with a high unmet medical need that require the detection of a range of pathogens, such as bacteria and fungi, as well as toxins and genetic antimicrobial resistance markers. It provides Unyvero L4 Lysator that is used for sample pre-processing and pathogen lysis; Unyvero A50 Analyzer, which consists of mechanical, electronic, pneumatic, and optical elements; Unyvero C8 Cockpit, a device that acts as the control panel for the L4 Lysator and A50 analyzer; and Unyvero LRT, a panel for various clinically relevant bacterial targets and antibiotic resistance markers. The company also offers Unyvero Application Cartridges, which facilitates the identification of a range of disease relevant microorganisms and antibiotic resistance markers for use in syndromic infectious disease testing; and ARES AMR Database, an Ai-curated database on the genetics of antimicrobial resistances. Its cartridge-based tests are used for pneumonia, implant and tissue, blood stream, intra-abdominal, and urinary tract infections. The company has strategic partnerships with MGI Tech Co. Ltd., Qiagen N.V., Biotest AG, and Sandoz International GMBH. Curetis N.V. was founded in 2007 and is headquartered in Holzgerlingen, Germany.